Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Model for Healthy Aging: Moscow Centenarians (AGE-100) (AGE-100)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02876809
Recruitment Status : Recruiting
First Posted : August 24, 2016
Last Update Posted : February 8, 2019
Sponsor:
Information provided by (Responsible Party):
Pirogov Russian National Research Medical University

Brief Summary:
This study evaluates the associations between biomarkers of ageing, comprehensive geriatric status, telomere length and progerin level, the composition of the gut microbiota, 16sRNA metagenome sequencing in Moscow centenarians.

Condition or disease
Aging

Detailed Description:
The global average life expectancy and the average age of the population are growing steadily along with the age-related diseases. The same trend is also observed in our country. Although, maximum life span in Russia decreases. E.g., the number of centenarians in Moscow decreased by 244 persons from 2013 to 2014. There were about 400 centenarians in Moscow in 2014. That is about 3.3 per 100 000 population. In the US, this figure is about 10-20, and there are 50 centenarians per 100 000 population in the Okinawa region, Japan. The rate of ageing varies substantially, a prime example of this is the centenarians population. These people break conventional stereotypes about aging. Chronic diseases in centenarians are postponed. They are more active, they work longer, they can better tolerate stressful situations. Scientists all over the world are trying to find the secret of their longevity. Studies on the medical and social aspects of centenarian longevity are actively carried out in the US, Europe, Japan, Australia. In Russia studies were carried out in St. Petersburg, Western and Eastern Siberia. According to the New England Centenarian Study, the supercentenarians (persons who have lived more than 110 years) life span is actually equal to the healthy span without serious illnesses. The aim of research is to study features of social status, lifestyle, habits, clinical status, blood chemistry, the amount of progerin, genome, composition of the gut microbiota in Moscow centenarians in order to create a model of healthy aging. In this study a comprehensive analysis of the longevity phenomenon of one hundred centenarians from Moscow and the Moscow region planning to be conducted. Analyzing of anamnesis vitae, medical, social, neuro-cognitive, and genetic features is planning. Each study participant will undergo a comprehensive geriatric assessment, including examination by the neurologist, an assessment of cognitive status,psychogeriatric consultation with the assessment of self-perceptions of aging and depression assessment by using the geriatric depression scale, neuropsychological testing using the Montreal Cognitive Assessment (MoCA), verbal recognition memory 12 word test, clock-drawing test.Telomere length and progerin level in buffy coat layer evaluation, 16sRNA metagenome sequencing, and nuclear magnetic resonance spectroscopy for qualitative and quantitative analysis of metabolites in blood serum, will be done in all participants. This study will take the science closer to the goal of identifying the patterns of "healthy" aging.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Model for Healthy Aging: Moscow Centenarians (AGE-100)
Actual Study Start Date : October 2016
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : December 2019



Primary Outcome Measures :
  1. Definition of frailty prevalence among 100-Centenarians [ Time Frame: 0 month ]
    Frailty will be measured by comprehensive geriatric assessment, including examination by the neurologist, an assessment of cognitive status,psychogeriatric consultation with the assessment of self-perceptions of aging and depression assessment by using the geriatric depression scale, neuropsychological testing using the Montreal Cognitive Assessment (MoCA), verbal recognition memory 12 word test, clock-drawing test


Secondary Outcome Measures :
  1. Definition of telomere biology status [ Time Frame: 0 month ]
    Relative telomere length in genomic DNA and telomerase activity in monocytes will be assessed by real-time PCR.

  2. Definition of vascular aging [ Time Frame: 0 month ]
    Vascular aging will be measured by intima-media thickness measurement and plaque presence determination by ultrasonography in both left and right common carotid arteries. Arterial stiffness will be assess by aortic pulse wave velocity measuring by SphygmoCor.


Biospecimen Retention:   Samples With DNA
Samples with DNA will be taken for telomere lenth, metabolome and metagenome definition


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   90 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Population consists of 100-age Moscow long-livers chosen according to data of Moscow clinics.
Criteria

Inclusion Criteria:

age over 90 years

Exclusion Criteria:

age under 90 years refusal to participate in the study


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02876809


Contacts
Layout table for location contacts
Contact: Olga N. Tkacheva, Professor +7 (499) 187-64-67 tkacheva@rambler.ru
Contact: Natalya V. Koroleva, PhD +7 (495) 434-36-23 koroleva_nv@rsmu.ru

Locations
Layout table for location information
Russian Federation
Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Russian Gerontology Clinical Research Center Recruiting
Moscow, Russian Federation, 115162
Contact: Olga N. Tkacheva, Professor    +7 (499) 187-64-67    tkacheva@rambler.ru   
Contact: Ekaterina N. Dudinskaya, PhD    +79031914690    katharina.gin@gmail.com   
Sponsors and Collaborators
Pirogov Russian National Research Medical University
Investigators
Layout table for investigator information
Principal Investigator: Olga N. Tkacheva, Professor Russian Gerontology Clinical Research Center